Positron emission tomography in prostate and renal cell carcinoma

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Purpose of review: The present review addresses technical improvements in [18F]deoxyglucose positron emission tomography (PET) and new tracer developments that may increase detection in prostate cancer and renal cell carcinoma. In addition, we discuss the future of molecular imaging in prostate cancer. Recent findings: PET has proven useful in imaging primary and metastatic cancer in a variety of tumor types. Previous work suggested that the most common radiopharmaceutical used in PET imaging -[18F]deoxyglucose - has a limited role in diagnosing primary prostate cancer and renal cell carcinoma. Technical improvements in scanning techniques and in PET scanners have increased detection of primary and metastatic lesions in both tumor types with [18F]deoxyglucose PET, as compared with previous studies. These improvements include increased scanner resolution and improved processing algorithms. In both prostate and renal cell carcinoma, however, better detection may result from the development of new tracers, particularly those that are not excreted into renal collecting systems. Labeled choline shows promise, as does [11C]acetate. New tracers for prostate cancer could be developed to detect changes that signal malignant transformation, as well as tracers that could show expression of genes administered for therapy. Summary: Technical improvements and the development of new tracers will probably make PET imaging a viable diagnostic tool in prostate cancer and renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)381-385
Number of pages5
JournalCurrent Opinion in Urology
Volume12
Issue number5
DOIs
StatePublished - Sep 2002

Fingerprint

Renal Cell Carcinoma
Positron-Emission Tomography
Prostate
Prostatic Neoplasms
Deoxyglucose
Neoplasms
Molecular Imaging
Radiopharmaceuticals
Choline
Genetic Therapy
Kidney

Keywords

  • Positron emission tomography
  • Prostate cancer
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Positron emission tomography in prostate and renal cell carcinoma. / Mathews, Dana; Öz, Orhan K.

In: Current Opinion in Urology, Vol. 12, No. 5, 09.2002, p. 381-385.

Research output: Contribution to journalArticle

@article{e758817bbee2473eb6628efbb63adda1,
title = "Positron emission tomography in prostate and renal cell carcinoma",
abstract = "Purpose of review: The present review addresses technical improvements in [18F]deoxyglucose positron emission tomography (PET) and new tracer developments that may increase detection in prostate cancer and renal cell carcinoma. In addition, we discuss the future of molecular imaging in prostate cancer. Recent findings: PET has proven useful in imaging primary and metastatic cancer in a variety of tumor types. Previous work suggested that the most common radiopharmaceutical used in PET imaging -[18F]deoxyglucose - has a limited role in diagnosing primary prostate cancer and renal cell carcinoma. Technical improvements in scanning techniques and in PET scanners have increased detection of primary and metastatic lesions in both tumor types with [18F]deoxyglucose PET, as compared with previous studies. These improvements include increased scanner resolution and improved processing algorithms. In both prostate and renal cell carcinoma, however, better detection may result from the development of new tracers, particularly those that are not excreted into renal collecting systems. Labeled choline shows promise, as does [11C]acetate. New tracers for prostate cancer could be developed to detect changes that signal malignant transformation, as well as tracers that could show expression of genes administered for therapy. Summary: Technical improvements and the development of new tracers will probably make PET imaging a viable diagnostic tool in prostate cancer and renal cell carcinoma.",
keywords = "Positron emission tomography, Prostate cancer, Renal cell carcinoma",
author = "Dana Mathews and {\"O}z, {Orhan K.}",
year = "2002",
month = "9",
doi = "10.1097/00042307-200209000-00003",
language = "English (US)",
volume = "12",
pages = "381--385",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Positron emission tomography in prostate and renal cell carcinoma

AU - Mathews, Dana

AU - Öz, Orhan K.

PY - 2002/9

Y1 - 2002/9

N2 - Purpose of review: The present review addresses technical improvements in [18F]deoxyglucose positron emission tomography (PET) and new tracer developments that may increase detection in prostate cancer and renal cell carcinoma. In addition, we discuss the future of molecular imaging in prostate cancer. Recent findings: PET has proven useful in imaging primary and metastatic cancer in a variety of tumor types. Previous work suggested that the most common radiopharmaceutical used in PET imaging -[18F]deoxyglucose - has a limited role in diagnosing primary prostate cancer and renal cell carcinoma. Technical improvements in scanning techniques and in PET scanners have increased detection of primary and metastatic lesions in both tumor types with [18F]deoxyglucose PET, as compared with previous studies. These improvements include increased scanner resolution and improved processing algorithms. In both prostate and renal cell carcinoma, however, better detection may result from the development of new tracers, particularly those that are not excreted into renal collecting systems. Labeled choline shows promise, as does [11C]acetate. New tracers for prostate cancer could be developed to detect changes that signal malignant transformation, as well as tracers that could show expression of genes administered for therapy. Summary: Technical improvements and the development of new tracers will probably make PET imaging a viable diagnostic tool in prostate cancer and renal cell carcinoma.

AB - Purpose of review: The present review addresses technical improvements in [18F]deoxyglucose positron emission tomography (PET) and new tracer developments that may increase detection in prostate cancer and renal cell carcinoma. In addition, we discuss the future of molecular imaging in prostate cancer. Recent findings: PET has proven useful in imaging primary and metastatic cancer in a variety of tumor types. Previous work suggested that the most common radiopharmaceutical used in PET imaging -[18F]deoxyglucose - has a limited role in diagnosing primary prostate cancer and renal cell carcinoma. Technical improvements in scanning techniques and in PET scanners have increased detection of primary and metastatic lesions in both tumor types with [18F]deoxyglucose PET, as compared with previous studies. These improvements include increased scanner resolution and improved processing algorithms. In both prostate and renal cell carcinoma, however, better detection may result from the development of new tracers, particularly those that are not excreted into renal collecting systems. Labeled choline shows promise, as does [11C]acetate. New tracers for prostate cancer could be developed to detect changes that signal malignant transformation, as well as tracers that could show expression of genes administered for therapy. Summary: Technical improvements and the development of new tracers will probably make PET imaging a viable diagnostic tool in prostate cancer and renal cell carcinoma.

KW - Positron emission tomography

KW - Prostate cancer

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0036738188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036738188&partnerID=8YFLogxK

U2 - 10.1097/00042307-200209000-00003

DO - 10.1097/00042307-200209000-00003

M3 - Article

C2 - 12172424

AN - SCOPUS:0036738188

VL - 12

SP - 381

EP - 385

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 5

ER -